Sofwave Medical’s New Study on Pure Impact Device: A Potential Game-Changer in Muscle Enhancement

Sofwave Medical Ltd. ((IL:SOFW)) announced an update on their ongoing clinical study.

Sofwave Medical Ltd. (IL:SOFW) is conducting a clinical study titled ‘Safety and Efficacy of Pure Impact to Strengthen and Tone Abdomen, Quadriceps and Glutes Muscles.’ The study aims to evaluate the safety and effectiveness of the Pure Impact device, which uses electrical muscle stimulation (EMS) to enhance muscle tone and strength. This research is significant as it explores non-invasive methods to improve muscle health, potentially benefiting a wide range of individuals seeking physical enhancement.

The intervention being tested is the Pure Impact device, an EMS module designed to deliver electrical impulses through electrodes placed on the skin near targeted muscles. The purpose of this intervention is to stimulate muscle activity, thereby increasing muscle tone and strength.

The study is designed as an open-label, non-randomized, prospective, single-center, self-controlled clinical trial. Participants are divided into two groups: an experimental group receiving the Pure Impact treatment and a control group with no intervention. The primary goal is to assess the treatment’s effectiveness in improving muscle condition.

The study began on July 29, 2025, with the latest update submitted on July 30, 2025. These dates are crucial as they mark the study’s initiation and the most recent progress update, indicating active recruitment and ongoing research.

The outcome of this study could significantly impact Sofwave Medical’s stock performance and investor sentiment. If successful, the Pure Impact device could position the company as a leader in the non-invasive muscle enhancement market, potentially influencing competitors and the broader industry landscape.

The study is currently recruiting, with further details available on the ClinicalTrials portal.